Find a story
Search Spins
Search titles, summaries, and missing voices across published articles — press releases, announcements, and media coverage.
12 results for “fiduciary duty”
Shareholder Alert: Ademi LLP investigates whether Fulcrum Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders
A law firm is investigating whether Fulcrum Therapeutics’ proposed acquisition by Slate Medicines undervalues the company and harms public shareholders’ interests.
Aug 17, 2026
Shareholder Alert: Ademi LLP investigates whether Blue Ridge Bankshares, Inc. is obtaining a Fair Price for Public Shareholders
A law firm is investigating whether Blue Ridge Bankshares' proposed merger with HomeTrust Bancshares violates fiduciary duties or other laws, raising concerns about fairness to public shareholders.
Aug 17, 2026
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)
A law firm has launched a preliminary investigation into ADMA Biologics' board for potential breaches of fiduciary duty, signaling possible shareholder litigation but no formal allegations or findings yet.
Aug 17, 2026
Shareholder Alert: Ademi LLP investigates whether Tri-County Financial Group, Inc. is obtaining a Fair Price for Public Shareholders
A law firm is investigating whether Tri-County Financial Group’s proposed transaction with HBT Financial violates fiduciary duties or securities laws, raising questions about fairness to public shareholders.
Aug 10, 2026
Shareholder Alert: Ademi LLP investigates whether Bowhead Specialty Holdings Inc. is obtaining a Fair Price for Public Shareholders
A law firm is investigating whether Bowhead Specialty Holdings Inc. received fair value for its shareholders in a transaction with American Family, raising questions about fiduciary duty and legal compliance.
Aug 3, 2026
Shareholder Alert: Ademi LLP investigates whether Supernus Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders
A law firm is investigating whether Supernus Pharmaceuticals' proposed transaction with Indivior Pharmaceuticals violates fiduciary duties or other laws, raising questions about fairness to public shareholders.
Aug 3, 2026
Shareholder Alert: Ademi LLP investigates whether MarketAxess Holdings Inc. is obtaining a Fair Price for Public Shareholders
A law firm has launched a shareholder investigation into MarketAxess’s proposed acquisition by Intercontinental Exchange, questioning whether public shareholders are receiving fair value.
Jul 30, 2026
Shareholder Alert: Ademi LLP investigates whether Safety Insurance Group, Inc. is obtaining a Fair Price for Public Shareholders
A law firm is investigating whether Safety Insurance Group's proposed acquisition by Mapfre delivers fair value to public shareholders, raising concerns about fiduciary duty compliance.
Jul 24, 2026
Shareholder Alert: Ademi LLP investigates whether BioLife Solutions, Inc. is obtaining a Fair Price for Public Shareholders
A law firm is investigating whether BioLife Solutions' proposed acquisition by Repligen offers fair value to public shareholders, raising questions about fiduciary obligations and transaction legality.
Jul 22, 2026
Shareholder Alert: Ademi LLP investigates whether AtaiBeckley Inc. is obtaining a Fair Price for Public Shareholders
A law firm is investigating whether AtaiBeckley Inc. violated fiduciary duties in its transaction with Eli Lilly, raising questions about fairness to public shareholders.
Jul 16, 2026
Shareholder Alert: Ademi LLP investigates whether TriCo Bancshares is obtaining a Fair Price for Public Shareholders
A law firm is investigating whether TriCo Bancshares provided fair value to public shareholders in its acquisition by First Hawaiian, raising questions about fiduciary duty compliance.
Jul 13, 2026
Shareholder Alert: Ademi LLP investigates whether Crinetics Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders
A law firm is investigating whether Crinetics Pharmaceuticals’ proposed transaction with Vertex constitutes a breach of fiduciary duty and fails to deliver fair value to public shareholders.
Jul 8, 2026